Myriad Genetics, Inc. (MYGN) reported an adjusted earnings per share (EPS) of 4 cents per share in the fourth quarter of 2023 versus the year-ago quarter’s loss of 12 cents. The metric surpassed the Zacks Consensus Estimate of 2 cents by 100%.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.The GAAP loss was 36 cents compared with the prior-year quarter’s loss of 52 cents.For the full year, the adjusted loss was 27 cen ...